Revolution Medicines is trading at $184.26, down 4.96%, after management cautioned that early launch demand may not reflect normalized sales. - Its November 4 report showed $197.6 million in RASONQUE revenue over roughly five weeks; early demand included finite patient transfers, pent-up demand and initial channel stocking. - Quarterly net loss widened to $407.5 million, and management expects operating expenses to rise in 2027. - The broader market was sharply lower, though biotech sector context was positive.